Enliven Therapeutics (ELVN)

Executive Summary

Enliven Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule kinase inhibitors for oncology, with a focus on improving survival and quality of life. Its lead programs include ELVN-001, a BCR-ABL inhibitor for chronic myeloid leukemia (CML), and ELVN-002, a HER2 inhibitor for HER2-mutant non-small cell lung cancer (NSCLC) and HER2-positive breast cancer. Both are in Phase 1 trials, with ELVN-001 showing potential to address resistance mutations and ELVN-002 targeting CNS-penetrant activity. The company’s precision medicine approach and experienced management team position it well, though clinical validation is still early. Recent data updates and upcoming milestones will be critical for advancing the pipeline and demonstrating differentiation from existing therapies.

Upcoming Catalysts (preview)

• Q4 2026ELVN-001 Phase 1 dose-escalation data update at ASH 202670% success
• Q3 2026ELVN-002 Phase 1 preliminary efficacy data in HER2-mutant NSCLC at ESMO 202660% success
• Q4 2026Initiation of ELVN-002 Phase 2 expansion cohorts in HER2-positive breast cancer75% success